(Q48516971)

12 February 2018

title

Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study (English)

1 reference

12 February 2018

0 references

G S Francis

1

1 reference

12 February 2018

M S Freedman

series ordinal

2

1 reference

12 February 2018

J P Antel

series ordinal

3

1 reference

12 February 2018

publication date

1 December 1997

1 reference

12 February 2018

Multiple Sclerosis Journal

published in

1 reference

12 February 2018

volume

3

1 reference

12 February 2018

issue

6

1 reference

12 February 2018

page(s)

370-376

1 reference

12 February 2018

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

cites work

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

The use of intravenous immune globulin in immunodeficiency diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

A Single Intravenous Infusion of Gamma Globulin as Compared with Four Infusions in the Treatment of Acute Kawasaki Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Acute renal failure resulting from intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Experience with intravenous immunoglobulin in myasthenia gravis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

High dose immunoglobulin IV treatment in adrenoleukodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Immunoglobulin treatment in human and experimental epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Manipulating the Immune System with Immune Globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Immunoglobulins reactive with myelin basic protein promote CNS remyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859700300602

10.1177/135245859700300602

21 January 2018

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018